Want to see GNLX full AI Analyst Report?
Top Page
Genelux Corp.
(NASDAQ:GNLX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-13.49% Downside)
Action:Reiterated
Date:08/07/26
The score is primarily held back by weak financial performance (minimal revenue, sizable losses, and heavy cash burn implying continued financing risk). Technicals also remain bearish with the stock trading below key moving averages and a negative MACD, though oversold RSI/Stoch readings provide a small offset. Valuation is constrained by negative earnings (negative P/E) and no indicated dividend support.
Positive Factors
Low financial leverage
Modest debt relative to equity provides structural financial flexibility and lowers near-term solvency risk. For a cash-burning biotech this reduces fixed interest obligations and gives management more optionality to fund R&D or seek partnerships before urgent capital raises, supporting program continuity.
Negative Factors
High cash burn
Sustained multi‑tens‑of‑millions annual cash burn is a structural vulnerability. It rapidly consumes available resources, forces recurring capital raises, and can disrupt long‑term program timelines if market conditions tighten, limiting the company's ability to complete trials or scale operations without dilution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Modest debt relative to equity provides structural financial flexibility and lowers near-term solvency risk. For a cash-burning biotech this reduces fixed interest obligations and gives management more optionality to fund R&D or seek partnerships before urgent capital raises, supporting program continuity.
Read all positive factors
Genelux Corp. (GNLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$131.83M
Dividend YieldN/A
Average Volume (3M)156.94K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue GrowthN/A
EPS Growth3.16%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding44,840,416
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue12.55K
Enterprise Value/Gross Profit-353.63
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$23.50Price Target Upside713.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Genelux Corp. Business Overview & Revenue Model
Company Description
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi...
How the Company Makes Money
null...
Genelux Corp. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.00K | 8.00K | 8.00K | 170.00K | 11.07M | 0.00 |
| Gross Profit | -284.00K | -566.00K | -895.00K | -848.00K | 10.10M | -895.00K |
| EBITDA | -32.04M | -31.57M | -28.97M | -26.46M | -1.73M | -13.67M |
| Net Income | -31.78M | -32.15M | -29.87M | -28.30M | -5.21M | -17.80M |
Balance Sheet | ||||||
| Total Assets | 32.37M | 19.03M | 34.72M | 27.89M | 5.53M | 8.13M |
| Cash, Cash Equivalents and Short-Term Investments | 26.21M | 14.60M | 30.89M | 23.19M | 397.00K | 4.50M |
| Total Debt | 2.50M | 1.69M | 1.87M | 2.52M | 26.35M | 25.31M |
| Total Liabilities | 9.45M | 7.48M | 8.44M | 8.42M | 41.31M | 41.24M |
| Stockholders Equity | 22.92M | 11.54M | 26.27M | 19.47M | -35.78M | -33.11M |
Cash Flow | ||||||
| Free Cash Flow | -27.88M | -26.37M | -21.61M | -21.30M | -3.62M | -6.58M |
| Operating Cash Flow | -25.89M | -25.27M | -21.23M | -20.27M | -3.57M | -6.58M |
| Investing Cash Flow | 93.00K | 12.14M | -8.13M | -14.72M | -49.00K | 0.00 |
| Financing Cash Flow | 18.87M | 9.89M | 28.51M | 44.02M | -478.00K | -270.00K |
Genelux Corp. Risk Analysis
Genelux Corp. disclosed 88 risk factors in its most recent earnings report. Genelux Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Genelux Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.57B | -16.72 | -106.16% | ― | ― | 63.03% | |
54 Neutral | $285.57M | -2.25 | -58.89% | ― | -52.64% | 26.97% | |
54 Neutral | $166.19M | -1.36 | -70.89% | ― | ― | -37.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $131.83M | -3.34 | -165.18% | ― | ― | 3.16% | |
47 Neutral | $217.49M | -1.10 | -182.27% | ― | -76.26% | -9.93% | |
47 Neutral | $159.57M | -0.68 | -67.65% | ― | 74.84% | 99.51% |
* Healthcare Sector Average
GNLX
Genelux Corp.
2.70
-0.64
-19.16%
CHRS
Coherus Biosciences
1.27
0.38
43.26%
FATE
Fate Therapeutics
2.49
1.51
154.08%
TNXP
Tonix Pharma
11.65
-35.27
-75.17%
CRBP
Corbus Pharmaceuticals
9.74
0.74
8.22%
FBRX
Forte Biosciences
76.83
66.53
645.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.